Darius A. Monsef IV

Bubs Australia secures permanent US FDA approval as shares surge

Bubs Australia has secured permanent FDA authorization to sell three infant formula products in the United States, converting temporary access into a durable, scalable footprint across more than 10,000 stores and laying the groundwork for potential private-label deals. While the milestone supports a US growth engine and potential margin improvements as costs unwind, investors caution that ongoing cash burn and financing needs remain risks as the company expands its operations.